Trobix Bio, 18 September 2019
Financing is a Testament of the Israeli Government’s Endorsement for the Groundbreaking Antibacterial Resistance Technology of Trobix Bio
Netanya, Israel, September 18, 2019
Trobix Bio, a newly established start-up with a unique set of proprietary phage-based antibiotic resistance sensitizing solutions, announced today that the Israel Innovation Authority (IIA) recently approved a grant for Trobix Bio to receive funding through the IIA “Early Stage Companies Incentive Program.” This funding will support the continuing development of novel products that abolish bacterial antibiotic resistance.
The IIA, previously known as the Office of the Chief Scientist of Israel’s Ministry of Economy, is an independent publicly funded agency, which acts as the support arm of the Israeli government to help facilitate the development of industrial R&D within the State of Israel.
“Trobix Bio is pioneering the development of products to treat the global crisis of antimicrobial resistance, and the support of our program by the IIA is proof of their confidence in the potential of Trobix Bio to combat antibiotic resistance with our unique technology,” said Dr. Adi Elkeles, Founder and CEO of Trobix Bio. “We are grateful for the financial support from the IIA, which complements our seed funding that was completed in March 2019, thus enabling us to spring board the development of our initial product pipeline.”
About Trobix Bio:
Trobix Bio has a unique set of proprietary phage-based antibiotic resistance sensitizing solutions to remove the threat of Antimicrobial Resistance. Our cutting-edge active sensitization technology, ActiSense™, applies selection pressure to reverse antibiotic resistance, thereby treating the core problem of the spread of antibiotic-resistant bacteria. Our proprietary GOTraP™ DNA delivery technology significantly extends DNA transduction into desired bacterial hosts.
Trobix Bio holds an exclusive worldwide license for this technology, which was invented by Prof. Udi Qimron and his team at Tel Aviv University in Israel. For further information, please contact:
Dr. Adi Elkeles
Founder & CEO
Tel: +972-54-6402333 | Email: firstname.lastname@example.org